Premium
Autoimmunity and Graves’ Disease
Author(s) -
Bahn R S
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.10
Subject(s) - clinical pharmacology , medicine , rituximab , monoclonal antibody , graves' disease , autoimmunity , antithyroid drugs , pharmacology , disease , immunology , antibody
Current treatment options for Graves’ hyperthyroidism and the related ophthalmopathy (GO) are not uniformly effective and carry with them potentially serious side effects. As a result, efforts have been focused on the development of novel therapies. Progress has been made, particularly in the production of thyroid‐stimulating hormone receptor (TSHR) antagonists, as either monoclonal blocking antibodies or small‐molecule ligands. In addition, rituximab (RTX) is the first targeted biological therapy to be studied as treatment for these conditions. Clinical Pharmacology & Therapeutics (2012); 91 4, 577–579. doi: 10.1038/clpt.2012.10